RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+49.07%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$1.43B
AUM Growth
+$1.43B
(-15%)
Cap. Flow
-$148M
Cap. Flow
% of AUM
-10.33%
Top 10 Holdings %
Top 10 Hldgs %
54.7%
Holding
66
New
3
Increased
9
Reduced
40
Closed
4
Top Buys
| 1 |
CBLL
CeriBell, Inc. Common Stock
CBLL
|
$11.3M |
| 2 |
RAPT Therapeutics
RAPT
|
$9.43M |
| 3 |
Neurogene
NGNE
|
$8.12M |
| 4 |
LivaNova
LIVN
|
$7.8M |
| 5 |
89bio
ETNB
|
$4.67M |
Top Sells
| 1 |
AUGX
Augmedix, Inc. Common Stock
AUGX
|
$38.5M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
$36.1M |
| 3 |
Scholar Rock
SRRK
|
$29.8M |
| 4 |
Kymera Therapeutics
KYMR
|
$11.8M |
| 5 |
Amicus Therapeutics
FOLD
|
$11.2M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
IDEAYA Biosciences
IDYA
$2.25B
| $15.9M | 1.11% |
619,300
-61,850
| -9% | -$1.59M |
|
27
Celldex Therapeutics
CLDX
$1.55B
| $15.6M | 1.08% |
615,775
-41,400
| -6% | -$1.05M |
|
28
Establishment Labs
ESTA
$1.11B
| $14.7M | 1.03% |
320,149
+58,346
| +22% | +$2.69M |
|
29
Immunovant
IMVT
$2.89B
| $14.2M | 0.99% |
571,824
-70,405
| -11% | -$1.74M |
|
|
CBLL
30
CeriBell, Inc. Common Stock
CBLL
$424M
| $11.3M | 0.79% |
+435,239
| New | +$11.3M |
|
31
Stryker
SYK
$147B
| $11M | 0.77% |
30,676
-2,065
| -6% | -$744K |
|
|
32
RAPT Therapeutics
RAPT
$191M
| $10.2M | 0.71% |
6,475,317
+5,970,785
| +1,183% | +$9.43M |
|
33
BioNTech
BNTX
$24.1B
| $9.51M | 0.66% |
83,471
-70,985
| -46% | -$8.09M |
|
34
Intuitive Surgical
ISRG
$156B
| $8.84M | 0.62% |
16,943
-9,755
| -37% | -$5.09M |
|
35
Keros Therapeutics
KROS
$642M
| $8.75M | 0.61% |
552,506
| – | – |
|
36
Nuvation Bio
NUVB
$1.04B
| $8.06M | 0.56% |
3,031,009
| – | – |
|
37
Ardelyx
ARDX
$1.56B
| $7.99M | 0.56% |
1,576,259
-84,504
| -5% | -$428K |
|
|
ORKA
38
Oruka Therapeutics, Inc. Common Stock
ORKA
$580M
| $7.98M | 0.56% |
411,728
| – | – |
|
|
VERV
39
DELISTED
Verve Therapeutics
VERV
| $7.43M | 0.52% |
1,318,164
-65,202
| -5% | -$368K |
|
40
Shattuck Labs
STTK
$61.8M
| $6.7M | 0.47% |
5,539,724
-75,765
| -1% | -$91.7K |
|
41
4D Molecular Therapeutics
FDMT
$293M
| $6.67M | 0.46% |
1,196,910
-65,180
| -5% | -$363K |
|
42
ALX Oncology
ALXO
$54.1M
| $6.16M | 0.43% |
3,689,611
-146,965
| -4% | -$245K |
|
43
Penumbra
PEN
$10.5B
| $6.11M | 0.43% |
25,743
+11,896
| +86% | +$2.83M |
|
44
Prime Medicine
PRME
$588M
| $6.06M | 0.42% |
2,074,350
| – | – |
|
45
Atara Biotherapeutics
ATRA
$87.6M
| $5.88M | 0.41% |
441,701
-10,569
| -2% | -$141K |
|
46
Cytokinetics
CYTK
$5.88B
| $4.36M | 0.3% |
92,598
-4,518
| -5% | -$213K |
|
47
Stereotaxis
STXS
$244M
| $4.1M | 0.29% |
1,799,465
-308,754
| -15% | -$704K |
|
|
ALLK
48
DELISTED
Allakos
ALLK
| $3.65M | 0.25% |
3,015,097
-62,731
| -2% | -$75.9K |
|
49
Astria Therapeutics
ATXS
$388M
| $3.1M | 0.22% |
346,278
+35,394
| +11% | +$316K |
|
50
AC Immune
ACIU
$230M
| $2.79M | 0.19% |
1,034,299
-659,868
| -39% | -$1.78M |
|